Olivier Wong

CMO
Medi-Qualite Omega SARL
​

 

Dr. Olivier Wong is the Chief Medical Officer at Medi-Qualite Omega SARL and a renowned consultant in the life sciences industry. With over two decades of experience, Dr. Wong has significantly contributed to strategic decisions, investments, and patient access, focusing on research and development, trial design, and health technology assessment (HTA). He is a sought-after expert advisor for governments and healthcare organizations globally.
Dr. Wong's professional journey began in France, where he was a key decision-maker from 1996 to 2016, influencing healthcare policies for 68 million people. He served as a voting member of the Transparency Committee and advisor to the ANSM, HAS, and the French Government. His work included shaping national guidelines on disease management, hospital certification, and drug pricing and reimbursement, with a particular focus on advanced therapy medicinal products (ATMP) and gene therapies.
From 2017 to 2023, Dr. Wong expanded his influence internationally, serving as a partner business consultant in HTA and pricing and reimbursement. He contributed to European Union research programs, developing new clinical trial endpoints for HTA evaluations. His expertise in HTA and pricing negotiations has enhanced patient access to innovative drugs across various regions.
Academically, Dr. Wong holds a Specialist in Family Medicine certification, a Master of Science from the University of Paris, and several advanced certificates in statistics, epidemiology, and data modeling. These qualifications underpin his analytical and strategic approach to healthcare.
Dr. Wong is a prolific author and contributor to medical literature and public health policy. He has written numerous articles, books, and reports on topics ranging from antibiotic use to healthcare system evaluations. 

Dr. Olivier Wong continues to shape the global healthcare landscape with his extensive experience and strategic vision, driving advancements in patient care and medical innovation.
 

Speech title & Synopsis

Navigating the Landscape: Global Perspectives on Financing Advanced Therapies

Advanced Therapy Medicinal Products (ATMPs), especially gene therapies, offer groundbreaking potential to treat the root causes of debilitating, chronic, and rare diseases. These therapies promise long-term efficacy and a safe, one-time administration, providing significant hope for patients and their caregivers.
Despite their potential, funding ATMPs poses considerable challenges, particularly in EOCD countries. Key issues include: uncertainty in clinical trials, target population doubts, funding limitations. The global landscape of ATMPs reveals significant disparities. North America leads in the number of developers and clinical trials, followed by Europe and Asia Pacific. Varying approval and funding statuses across countries further complicate access to these therapies.
Current reimbursement policies prioritize effect size as a critical driver for access decisions. The need for clear, transparent, and reproducible criteria is paramount. Gene therapies targeting conditions like hemophilia are particularly compelling due to the economic and clinical burdens of current care standards, making them ideal candidates for innovative payment models.
To fully realize the potential of ATMPs, we must establish robust definitions of success, minimize litigation risks, and negotiate sustainable payment models. Collaboration among healthcare providers, patients, financial officers, and policymakers is crucial in this endeavor.